NBT-NM108 / Notitia Biotech - LARVOL DELTA

HFS (High-Fiber Supplement) in MS (Multiple Sclerosis) (clinicaltrials.gov) - P1/2 | N=7 | Completed | Sponsor: Suhayl Dhib-Jalbut, MD | Enrolling by invitation ➔ Completed | N=50 ➔ 7

Enrollment change • Trial completion • CNS Disorders • Multiple Sclerosis • TNFA

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery (clinicaltrials.gov) - P2 | N=42 | Recruiting | Sponsor: Howard S. Hochster, MD | Trial completion date: Sep 2024 ➔ Jul 2025 | Trial primary completion date: Jan 2024 ➔ Jul 2025

Trial completion date • Trial primary completion date • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

HFP (High-Fiber Supplement) in MS (Multiple Sclerosis) (clinicaltrials.gov) - P1/2 | N=50 | Enrolling by invitation | Sponsor: Suhayl Dhib-Jalbut, MD | Trial completion date: Sep 2023 ➔ Sep 2024 | Trial primary completion date: Sep 2022 ➔ Jun 2024

Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis • FOXP3

COVGUT20: NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients (clinicaltrials.gov) - P2 | N=44 | Completed | Sponsor: Notitia Biotechnologies Company | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery (clinicaltrials.gov) - P2 | N=42 | Recruiting | Sponsor: Howard S. Hochster, MD | Trial completion date: Sep 2023 ➔ Sep 2024 | Trial primary completion date: Jun 2023 ➔ Jan 2024

Trial completion date • Trial primary completion date • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

PWSGUT: Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome (clinicaltrials.gov) - P2 | N=12 | Completed | Sponsor: Rutgers, The State University of New Jersey | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity • Prader–Willi syndrome

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery (clinicaltrials.gov) - P2 | N=42 | Recruiting | Sponsor: Howard S. Hochster, MD | Trial primary completion date: Mar 2023 ➔ Jun 2023

Trial primary completion date • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

PWSGUT: Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: Rutgers, The State University of New Jersey | Trial completion date: Feb 2023 ➔ Jul 2023

Trial completion date • Genetic Disorders • Obesity • Prader–Willi syndrome

PWSGUT: Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: Rutgers, The State University of New Jersey | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity • Prader–Willi syndrome

PWSGUT: Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: Rutgers, The State University of New Jersey | Trial completion date: Dec 2023 ➔ Feb 2023

Trial completion date • Genetic Disorders • Obesity • Prader–Willi syndrome

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery (clinicaltrials.gov) - P2 | N=42 | Recruiting | Sponsor: Howard S. Hochster, MD | Not yet recruiting ➔ Recruiting

Enrollment open • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

PWSGUT: Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: Rutgers, The State University of New Jersey

New P2 trial • Genetic Disorders • Obesity • Prader–Willi syndrome

COVGUT20: NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients (clinicaltrials.gov) - P2 | N=44 | Active, not recruiting | Sponsor: Notitia Biotechnologies Company | Recruiting ➔ Active, not recruiting | N=100 ➔ 44 | Trial completion date: Jan 2022 ➔ Dec 2022 | Trial primary completion date: Dec 2021 ➔ Apr 2022

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Microbiotic Product (NBT-NM108) to Reduce Chemotherapy-Induced Diarrhea (clinicaltrials.gov) - P2 | N=42 | Not yet recruiting | Sponsor: Howard S. Hochster, MD

New P2 trial • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

HFP (High-Fiber Supplement) in MS (Multiple Sclerosis) (clinicaltrials.gov) - P1/2; N=50; Enrolling by invitation; Sponsor: Suhayl Dhib-Jalbut, MD; Not yet recruiting ➔ Enrolling by invitation

Enrollment open • CNS Disorders • Multiple Sclerosis • FOXP3

NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: Notitia Biotechnologies Company; Trial completion date: Jun 2021 ➔ Nov 2021; Initiation date: Feb 2021 ➔ May 2021; Trial primary completion date: May 2021 ➔ Oct 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

NBT-NM108 as an Early Treatment of Suspected or Confirmed COVID-19 in Patients With Prediabetes or Type 2 Diabetes (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: Notitia Biotechnologies Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Type 2 Diabetes Mellitus

NBT-NM108 as an Early Treatment of Suspected or Confirmed COVID-19 in Patients With Prediabetes or Type 2 Diabetes (clinicaltrials.gov) - P2; N=100; Not yet recruiting; Sponsor: Notitia Biotechnologies Company; Trial completion date: Mar 2021 ➔ Jun 2021; Initiation date: Oct 2020 ➔ Jan 2021

Clinical • Trial completion date • Trial initiation date • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Type 2 Diabetes Mellitus

HFP (High-Fiber Supplement) in MS (Multiple Sclerosis) (clinicaltrials.gov) - P1/2; N=50; Not yet recruiting; Sponsor: Suhayl Dhib-Jalbut, MD

New P1/2 trial • CNS Disorders • Multiple Sclerosis • FOXP3

NBT-NM108 as an Early Treatment of Suspected or Confirmed COVID-19 in Patients With Prediabetes or Type 2 Diabetes (clinicaltrials.gov) - P2; N=100; Not yet recruiting; Sponsor: Notitia Biotechnologies Company

Clinical • New P2 trial • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Type 2 Diabetes Mellitus